CD40LG and Sepsis: E5, a murine anti-lipid A IgM mAb isolated by Lowell Young at UCLA (U.S. patent 4918163) and licensed to Xoma (Xomen-E5), and HA-1A, a human anti-lipid A IgM mAb isolated by Nelson Teng at Stanford [146] and licensed to Centocor (as Centoxin), entered clinical trials for sepsis in the early 1980s; both IgMs were evaluated in a number of clinical trials, and product license applications (PLAs) for both products were submitted to the FDA in early 1989 [147].